

Special Issue

T and B Cell Responses to HIV and Tuberculosis Infections/Coinfection and Vaccinations

Message from the Guest Editor

Given the equal importance of T and B cell immunity in HIV/Mtb infections, coinfection, and vaccinations, the following aspects are of interest in this Special Issue:

- Characterization of T and B cell immunity after HIV and/or Mtb infections and coinfection using human cohorts.
- Develop vaccines for HIV/Mtb single infections or coinfection and test their efficacy in appropriate animal models.
- Characterizing T and B cell epitopes and testing their potential for vaccine development.
- Identify novel T cell subsets or new functions of existing T cell subsets during HIV/Mtb infections and coinfection.
- Profiling of TCR/BCR after infections or vaccinations using high-throughput T/B cell receptor sequencing technology.
- Exploration of novel techniques to characterize T and B cell immune responses to HIV/Mtb infections.

Guest Editor

Dr. Guohua Yi

Center for Biomedical Research, University of Texas Health Center at Tyler, Tyler, TX, USA

Deadline for manuscript submissions

closed (31 December 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/213335

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).